Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $180.00 price target on the stock.
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack [Yahoo! Finance]Yahoo! Finance
- Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices [Yahoo! Finance]Yahoo! Finance
- Repligen Purchases Bioprocessing Analytics Portfolio from 908 DevicesGlobeNewswire
- Repligen Co. (NASDAQ: RGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank of Canada from $203.00 to $205.00. They now have an "outperform" rating on the stock.MarketBeat
RGEN
Earnings
- 2/20/25 - Beat
RGEN
Sec Filings
- 3/4/25 - Form 4
- 3/4/25 - Form 4
- 3/4/25 - Form 4
- RGEN's page on the SEC website